ClinicalTrials.gg
RecruitingNCT06945315Updated Apr 25, 2025

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

A Phase 3 interventional study of RALP (Robotic-assisted radical prostatectomy) and SAFE (Saline assisted fascial engorgement) in Prostate Cancer and Erectile Dysfunction, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Nov 2023, registered Apr 2025).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai — 5 open to participants now, 7 under way, 1 of them phase 3. Prostatic Neoplasms · Icahn School of Medicine at Mount Sinai.

Planned enrollment
3rd of 12
196 · median 40
Started
2023
with 1 other
Phase 3
Only one
of the 15
Registered
11th of 15
by date

Among the 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 3, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the management of localized prostate cancer. However, post-prostatectomy erectile dysfunction (ED) and urinary incontinence still pose a challenge that adversely affects the patient's quality of life. Hydrodissection (HD) was introduced in 1987 in the medical field and it was tested for the first time during a retropubic radical prostatectomy back in 2005. Since then, research has indicated an improvement in erectile function results, presumably because of a less traumatic neural dissection and a decreased risk of neuropraxia. In an effort to achieve a balance between oncological excision and functional preservation, prostate surgery is evolving to incorporate intraoperative real-time evaluation of extracapsular extension. Recently, a micro-ultrasound operating at 29 MHz has been introduced. It provides a resolution down to 70 μ to assess the glandular pattern and cellular density of the prostatic tissue. Given the experience in more than a thousand cases with this technology, and the growing literature showing promising results in the detection and staging of prostate cancer; the researchers decided to implement this tool as guidance for hydrodissection of the layers of the lateral prostatic fascia.

Robotic-Assisted Laparoscopic Prostatectomy and SAFE (Saline assisted fascial engorgement) nerve preservation guided by Microultrasound (MUS) is a prospective randomized controlled trial designed to evaluate the impact of normal saline solution hydrodissection (HD) on erectile function outcomes after RALP. This innovative approach consists of a transrectal ultrasound-guided HD using a high-resolution Microultrasound (MUS) (ExactVu micro-ultrasound, Exact Imaging, Markham, Canada). The technique will be applied to those patients who undergo grade 1, 2, or 3 NS approach taking into account the grading system proposed by Tewari et al.

The hypothesis is that the SAFE technique could minimize the risk of a traumatic neurovascular bundle dissection while assessing the prostatic capsule integrity with a high-resolution MUS. The researchers also hypothesize that the use of SAFE along with RALP will optimize the post-surgery recovery of erectile function.

03

Conditions studied

  • Prostate Cancer
  • Erectile Dysfunction

Keywords

  • Robotic-Assisted Laparoscopic Prostatectomy (RALP)
  • SAFE (Saline assisted fascial engorgement)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years at the time of consent.
  • Men who are potent (SHIM ≥ 17) and sexually active, who are planned to undergo a grade 1, 2, or 3 nerve-sparing approaches, as per the grading system during RALP.
  • Ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Subjects who are candidates for salvage RALP
  • Subjects on androgen deprivation therapy (ADT)
  • Subjects in whom PDE5 inhibitors are
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    RALP with SAFE Technique

    Erectile function recovery will be evaluated for patients receiving Robotic-Assisted Laparoscopic Prostatectomy (RALP) + SAFE (Saline assisted fascial engorgement).

    Procedure: RALP (Robotic-assisted radical prostatectomy) · Drug: SAFE (Saline assisted fascial engorgement)

  • Active comparator
    RALP without SAFE Technique

    Erectile function recovery will be evaluated for patients receiving Robotic-Assisted Laparoscopic Prostatectomy (RALP) without SAFE (Saline assisted fascial engorgement).

    Procedure: RALP (Robotic-assisted radical prostatectomy)

Interventions

  • ProcedureRALP (Robotic-assisted radical prostatectomy)

    Robotic-assisted radical prostatectomy (RALP) is a standard surgical procedure for managing localized prostate cancer that focuses on prostate anatomy and surrounding structures to enable personalized surgeries. The procedure incorporates nerve-sparing techniques through careful dissection of the neurovascular bundle and can use a thermal and traction-free dissection to improve functional outcomes, particularly erectile function.

  • DrugSAFE (Saline assisted fascial engorgement)

    SAFE (Saline assisted fascial engorgement) an innovative technique to achieve enhanced nerve-sparing outcomes among patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). Essentially a new method of hydro dissection, SAFE involves an injection of 30 cc of normal saline solution between the layers of the periprostatic fascia after early release of the neurovascular bundle. This injection effectively pushes the nerves away from the prostate, enabling a dissection of the prostate that is atraumatic vis a vis the neural hammock.

06

What researchers measure

Primary outcomes

  1. Sexual Health Inventory for Men (SHIM)

    The Sexual Health Inventory for Men (SHIM) is a five-question, abbreviated, validated questionnaire derived from the International Index of Erectile Function questionnaire. It is widely used by urologists to evaluate efficacy of ED treatments. It is graded on a scale of 1-25, with higher scores indicating no signs of erectile dysfunction.

    Time frame: Baseline (Week 0), 6 weeks, 3-months, 6-months, 12-months and 24-months following surgery

Secondary outcomes

  1. The Erection Hardness Score (EHS)

    The Erection Hardness Score (EHS) is tool used to evaluate and monitor the severity of ED. It is a four-point scale (1-4), with a score of 4 indicating a completely hard and fully rigid erection. Higher score indicates better health outcomes.

    Time frame: Baseline (Week 0), 6 weeks, 3-months, 6-months, 12-months and 24-months following surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Informed consent form

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. Any purpose. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in ISMMS data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (to be determined).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 44 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 25, 2025
StartActual
Nov 14, 2023
Primary completionEst.
Jul 14, 2027
CompletionEst.
Jul 14, 2027
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06945315
Responsible party
Ashutosh Kumar Tewari (Professor and System Chair, Milton and Carroll Petrie Department of Urology. Director of Center of Excellence for Prostate Cancer at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Apr 25, 2025
Start date
Nov 14, 2023
Primary completion
Jul 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Apr 25, 2025

Study contacts

Neeraja Tillu
Contact
Neeraja.tillu@mountsinai.org
(332) 256-8528
Monali Fatterpekar, PhD
Contact
monali.fatterpekar@mountsinai.org
(212) 241-0751
Ashutosh Kumar Tewari, MBBS, MCh, FRCS (Hon.)
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion